These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22473458)

  • 21. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
    Miyazaki S; Kasai T; Miyauchi K; Miyazaki T; Akimoto Y; Takagi A; Aihara K; Kawamura M; Suwa S; Kojima S; Sumiyoshi M; Daida H
    Circ J; 2010 Jun; 74(6):1158-64. PubMed ID: 20378999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
    Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valsartan after myocardial infarction.
    Güleç S
    Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S9-13. PubMed ID: 25604205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
    Prisant LM; Thomas KL; Lewis EF; Huang Z; Francis GS; Weaver WD; Pfeffer MA; McMurray JJ; Califf RM; Velazquez EJ
    J Am Coll Cardiol; 2008 May; 51(19):1865-71. PubMed ID: 18466801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of the VALIANT trial in post-myocardial infarction].
    Solignac M
    Presse Med; 2004 Jun; 33(11):755-8. PubMed ID: 15257233
    [No Abstract]   [Full Text] [Related]  

  • 31. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From black and white to shades of gray: race and renin-angiotensin system blockade.
    Havranek EP
    J Am Coll Cardiol; 2008 May; 51(19):1872-3. PubMed ID: 18466802
    [No Abstract]   [Full Text] [Related]  

  • 33. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 37. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
    Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
    Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
    Ishii H; Kobayashi M; Kurebayashi N; Yoshikawa D; Suzuki S; Ichimiya S; Kanashiro M; Sone T; Tsuboi H; Amano T; Uetani T; Harada K; Marui N; Murohara T
    Am J Cardiol; 2013 Aug; 112(3):363-8. PubMed ID: 23623047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
    Steely AM; Callas PW; Bertges DJ;
    J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.